16/10/2014 08:42:21

EXINI to arrange Bone Scan Index (BSI) symposium at important annual European congress

Lund, Sweden, 2014-10-16 09:42 CEST (GLOBE NEWSWIRE) --

EXINI and FUJIFILM RI Pharma will arrange a Bone Scan Index (BSI) symposium on

October 20th at this year’s EANM-congress (European Association of Nuclear

Medicine) held in Gothenburg, October 18-22.

The symposium called ”Bone Scan Index (BSI) A Nuclear Medicine Biomarker in

Metastatic Prostate Cancer”, commence at 13.00 p.m. For more information >>


”The symposium provide a unique opportunity for invited physicians within

nuclear medicine, to learn more about the imaging biomarker BSI and its

clinical applications. Arranging it together with our partner FUJIFILM RI

Pharma adds extensive clinical experience and insights gained from the success

of our product EXINI boneBSI (Bonenavi) on the Japanese market ”, comments

Magnus Aurell, CEO, EXINI Diagnostics AB.

Throughout the congress, several academic studies based upon use of the

software EXINI boneBSI and its BSI-calculating capacity, will be presented:

OP365: Prognostic value of bone scan index for treatment response and survival

in patients with high-risk prostate cancer. M. Reza, A. Bjartell, M. Ohlsson,

R. Kaboteh, P. Wollmer, L. Edenbrandt, E. Trägård

P491: Analytical validation of automated bone scan index as a candidate imaging

biomarker for advanced prostate cancer. A. Anand, L. Edenbrandt, A. Bjartell,

D. Minarik

P502: Reproducibility of automated bone scan index in patients with advanced

prostate cancer. A. Anand, L. Båth, R. Kaboteh, A. Bjartell, L. Edenbrandt

P786: Routine usefulness analysis of computer assisted diagnosis (CAD) software

for bone scan index L. Ferrer, M. Colombie, D. Rusu, D. Goulon, B. Jamet, N.

Varmenot, F. Kraeber-Bodere, C. Rousseau

More on Bone Scan Index (BSI):

BSI is an imaging biomarker providing fast, accurate and quantifiable

information to be used for diagnosis and stratification and the monitoring of

treatment response. It also provides increased accuracy in prognoses involving

patients suffering from skeletal metastases originating from prostate- or

breast cancer.

What is more, BSI has demonstrated its importance in the process of developing

new drugs, thus proving itself just as important for clinical use as for the

pharmaceutical industry. EXINI boneBSI is the only software capable of

extracting BSI-values for both these purposes.



For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46 286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision

support to hospitals worldwide. The system is based on advanced image analysis

by artificial intelligence and can make its own interpretation of medical

images and provide diagnostic suggestions. In this way the system is used as a

decision support for the diagnosing doctor. EXINI is working with products for

the diagnosis of some of the most frequent endemic diseases such as cancer,

coronary heart disease, dementia and Parkinson's disease. The company was

founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock

market NASDAQ OMX First North and has about 600 shareholders. Principal owner

is Bo Håkansson. Consensus acts as Certified Adviser.


EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70

Lund, Sweden

Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com,


Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 May
  Jeg har flere gange analyseret Pandora, senest den 20 april og inden da efter årsregnskabet i febr..
22 May
Hej IceT : Det er kloge ord, du kommer med her. Jeg trak mig tilbage, da jeg var 53 år. Min arbejdsp..
20 May
LCB84 Earnings yield er jo den omvendte P/E, og dermed det direkte afkast du får af den pris aktien ..
23 May
For nogle af mine kunder, laver jeg en kvartals-analyse over, hvordan de Nordiske selskabers indtjen..
20 May
investor1 Her er lidt indspark til din vurdering. Pandora tjener aktuelt 53 kr. pr. aktie om året. J..
19 May
tak til Kranen og andre, for at smide lidt guld ud i form af info.   Men guldet kom først her:   htt..
19 May
Slap dog af bamse. 1.000 i 2017 er et temmelig vildt gæt. Og det er vel at mærke et gæt, du giver jo..
23 May
Hold øje med at politikere og andre nu som sædvanligt vil mane os til "at stå sammen" og "ikke lade ..
20 May
Super flot Alf. Gid vi alle (mig selv incl.) ville kunne levere tilsvarende bidrag til dette forum. ..
19 May
Det har også været min store bekymring, så jeg skrev en mail til deres IR-afdeling:   Min mail:   De..

PayPoint plc : Dividend Declaration

25/05/2017 10:11:47
25 May 2017 PayPoint plc - Dividends The board of directors of PayPoint plc (the "Company") has recommended the payment of a final dividend of 30 pence per share, in respect of the period ended 31 March 2017. The board has also declared an additional dividend of 24.5 pence per share. Subject to approval of shareholders of the final dividend at the Company's annual general meeting to be h..

PayPoint plc : Preliminary Results

25/05/2017 07:00:36
PayPoint plc  Preliminary results Year ended 31 March 2017 STATUTORY HIGHLIGHTS   Year ended 31 March 2017 Year ended 31 March 2016     Change Revenue £211.9m £212.6m (0.3)% Net rev..

Nasdaq to Deliver Post-Trade Technology to Depósito Central de Valores (DCV)

24/05/2017 14:00:20
The Chilean central securities depository (CSD) will boost its infrastructure capabilities and increase efficiencies with fully-fledged CSD solution based on the Nasdaq Financial Framework NEW YORK and SANTIAGO, Chile, May 24, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) and Depósito Central de Valores (DCV)  today announced a new landmark agreement to bolster the technological infrastru..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Neurotrope, Inc. (Nasdaq: NTRP) To Contact Brower Piven Before The Lead Plaintiff Deadline
Mesoblast Operational Highlights and Financial Results for the Period Ended March 31, 2017
Sysco to Webcast Presentation From the 2017 Goldman Sachs Lodging, Gaming, Restaurant and Leisure Conference
Expected Closing Date for Western Refining Acquisition and Election Deadline Announced
Ansaldo Energia S.p.A. BNP Paribas Primary New Issues : PRE-Stabilisation Notice

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
25 May 2017 11:29:12
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170517.1 - EUROWEB3 - 2017-05-25 12:29:12 - 2017-05-25 11:29:12 - 1000 - Website: OKAY